Emerald Investment Advisers’s Viking Therapeutics VKTX Stock Holding History

Emerald Investment Advisers’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$209K	Buy	+5,346	New	+$173K	0.01%	263

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Emerald Investment Advisers's VKTX Position: Q2 2026 in Review

Emerald Investment Advisers opened a new position in Viking Therapeutics (VKTX) in Q2 2026: 5,346 shares worth $209K. The stake represents 0.01% of the portfolio and ranks #263 among its holdings.

432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

Emerald Investment Advisers held 5,346 shares of Viking Therapeutics worth $209K as of Q2 2026.
Viking Therapeutics was a new Emerald Investment Advisers position in Q2 2026.
Viking Therapeutics made up 0.01% of Emerald Investment Advisers's portfolio in Q2 2026, its #263 holding.
432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Emerald Investment Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.